IPTACOPAN ASH UPDATE

There was no significant difference between iptacopan monotherapy and SoC for change from baseline in LDH level Mean LDH level (SD) during the 24-week randomized treatment period Mean LDH, U/L (SD) 900 800 700 600 500 400 300 200 100 H I 1.5 x ULN ULN ■ As expected, with all patients having been treated with anti-C5s prior to entering the study, IVH was well controlled and LDH levels <1.5x ULN in the vast majority of patients 0 BL Wk1Wk2 Wk4 Wk6 Wk8 Wk12 Patients with available data Iptacopan 62 61 61 Anti-C5 SoC 35 28 28 Study visit Wk16 Wk18 Wk20 Wk22 Wk24 ■ No difference in LDH levels shows that iptacopan maintains IVH control 61 62 62 34 34 34 62 34 61 59 59 57 61 34 35 33 32 35 Adjusted geometric mean ratio to baseline¹ in log-transformed LDH (95% CI) was 0.96 (0.90, 1.03) for iptacopan vs 0.98 (0.89, 1.07) for SoC, equating to a reduction of 1.15% (95% CI -10.18, 11.32) with iptacopan vs SoC (P=0.83452). 1. Between Days 126 and 168. 2. A repeated measures model, adjusting for covariates including baseline LDH, was used for comparisons between the treatment arms. P value is two-sided and unadjusted. ULN = upper limit of normal 16 IPTACOPAN ASH UPDATE | DECEMBER 13, 2022 NOVARTIS | Reimagining Medicine

View entire presentation